Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives $4.25 Average Price Target from Analysts

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has earned a consensus rating of “Hold” from the seven brokerages that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $4.25.

INO has been the subject of several research analyst reports. Wall Street Zen cut shares of Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Sunday, June 21st. HC Wainwright dropped their target price on Inovio Pharmaceuticals from $3.00 to $2.50 and set a “neutral” rating for the company in a research report on Monday, June 1st. Finally, Weiss Ratings cut Inovio Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, July 1st.

Hedge Funds Weigh In On Inovio Pharmaceuticals

Large investors have recently bought and sold shares of the business. Eversept Partners LP acquired a new stake in Inovio Pharmaceuticals during the 1st quarter worth $1,802,000. Renaissance Technologies LLC raised its position in shares of Inovio Pharmaceuticals by 16.4% during the 1st quarter. Renaissance Technologies LLC now owns 643,777 shares of the biopharmaceutical company’s stock valued at $1,120,000 after acquiring an additional 90,613 shares during the last quarter. Caitong International Asset Management Co. Ltd lifted its stake in shares of Inovio Pharmaceuticals by 1,929.4% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 48,948 shares of the biopharmaceutical company’s stock valued at $85,000 after purchasing an additional 46,536 shares during the period. Virtu Financial LLC acquired a new position in shares of Inovio Pharmaceuticals in the 4th quarter valued at $77,000. Finally, Janus Henderson Group PLC lifted its stake in shares of Inovio Pharmaceuticals by 1.3% in the 4th quarter. Janus Henderson Group PLC now owns 3,308,406 shares of the biopharmaceutical company’s stock valued at $5,773,000 after purchasing an additional 42,146 shares during the period. 26.79% of the stock is currently owned by institutional investors and hedge funds.

Inovio Pharmaceuticals Stock Performance

Inovio Pharmaceuticals stock opened at $1.10 on Friday. The firm has a market cap of $90.50 million, a P/E ratio of -0.76 and a beta of 1.48. The business’s fifty day moving average is $1.18 and its two-hundred day moving average is $1.39. Inovio Pharmaceuticals has a 52 week low of $1.03 and a 52 week high of $2.98.

Inovio Pharmaceuticals (NASDAQ:INO) last announced its earnings results on Wednesday, May 13th. The biopharmaceutical company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.02. On average, equities research analysts predict that Inovio Pharmaceuticals will post -1.03 earnings per share for the current year.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.